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Abstract
Background: Thymic carcinoma is a rare neoplasm with extremely poor prognosis. To evaluate
the biological characteristics of thymic carcinoma, we reviewed 8 patients.
Methods: There were 2 men and 6 women: ages ranged from 19 to 67 years old (mean 54.8
years). None of these patients had concomitant myasthenia gravis and pure red cell aplasia. No
patient had stage I disease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic subtypes of thymic
carcinoma included 5 squamous cell carcinomas, 1 adenosquamous cell carcinomas, 1 clear cell
carcinoma, and 1 small cell carcinoma. Immunohistochemical study was performed using antibodies
against p53, bcl-2, Ki-67, carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA),
nm23-H1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and
factor VIII.
Results: Curative resection could be done in 4 patients (50%). Our data indicates a trend toward
an association between complete resection and patient survival. Expression of p53, bcl-2, CEA,
EMA, nm23-H1, VEGF and FGF-2 was detected in 5/8, 3/8, 4/8, 5/8, 6/8, 5/8 and 3/8, respectively.
Mean Ki-67 labeling index and microvessel density was 7.01 and 34.36 (per 200×  field), respectively.
When compared with our previous studies, immunohistochemical staining of these proteins in
thymomas, the expression rates of these proteins in thymic carcinomas were higher than those in
thymomas.
Conclusions: In this small series, it is suggested that a complete resection suggests a favorable
result. Immunohistochemical results reveal that the expression of these proteins might indicate the
aggressiveness of thymic carcinoma.
Background
Thymic carcinoma is a rare type of malignant tumor [1,2].
It is more invasive and with a poorer prognosis than ordi-
nary thymoma [3–8]. At diagnosis, it is usually invasive or
metastatic and complete curative resection is sometimes
not possible to achieve. There are no uniform manage-
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ment protocols and thymic carcinoma is treated by the
same guidelines used for thymomas, despite having a
more aggressive histologic appearance and clinical out-
come [6–8].
In addition, in spite of numerous previous studies about
expression of oncogene proteins in human cancers, very
little attention has been given to the biological character-
istics of thymic carcinoma [9–13].
To evaluate the outcome and biological characteristics of
thymic carcinomas, we reviewed patients undergoing
treatment including surgery at our hospital. In addition to
clinical analysis, we also investigated expression of some
cancer-related proteins to evaluate their biological charac-
teristics. Since previous studies of ours demonstrated the
expression p53, bcl-2, Ki-67, carcinoembryonic antigen
(CEA), epithelial membrane antigen (EMA), nm23-H1,
vascular endothelial growth factor (VEGF), basic fibrob-
last growth factor (FGF-2) and microvessels in thymomas
[14,15], we performed immunohistochemistry using
same antibodies as in our previous studies.
Methods
Patients
Between 1988 and 2000, 8 patients with thymic carcino-
ma who were treated surgically at Miyazaki Medical Col-
lege were included in this study. Two patients who did not
receive surgical options during this period were excluded.
There were 2 men and 6 women: ages ranged from 19 to
67 years old (mean 54.8 years). None of these patients
had concomitant myasthenia gravis and pure red cell
aplasia. Postoperative staging was made according to the
Masaoka staging system [16]. No patient had stage I dis-
ease, 1 stage II, 5 stage III, and 2 stage IV. The pathologic
subtypes of thymic carcinoma included 5 squamous cell
carcinomas, 1 adenosquamous cell carcinomas, 1 clear
cell carcinoma, and 1 small cell carcinoma. The histologic
grading was based on cell differentiation, which was mod-
ified from Suster and Rosai's classification system [4]. Car-
cinoid tumors, well-differentiated (keratinizing)
squamous cell carcinoma, and mucoepidermoid carcino-
ma were delegated to low-grade tumors, and all other
types were classified as high-grade tumors. In our series,
only one patient with squamous cell carcinoma had low-
grade tumor. Table 1 summarizes the clinical characteris-
tics of these patients. The mean follow-up period ranged
from 12 to 83 months (mean 30.8 months). The follow-
up information, including cause of death, was acquired
through clinic follow-up notes and direct or family con-
tact.
Immunohistochemical studies
Surgically resected tissue samples previously fixed in for-
malin and embedded in paraffin were used. The specific
antibodies against p53 (Dako, Glostrup, Denmark), bcl-2
(Dako), EMA (Dako), CEA (Dako), nm23-H1 (Novocas-
tra Laboratories, Newcastle, UK), Ki-67 (Immunotech,
Marseille, France), VEGF (Santa Cruz Biotechnology, Cal-
ifornia, U.S.A.), FGF-2 (Santa Cruz Biotechnology) and
factor VIII (Dako) were used in this study.
Before staining, serial 4 µm-thick sections were pre-treated
with microwave heating in 10 mM citric acid buffer for 4
×  5 min. These sections were immersed in 0.6% H2O2 in
methanol for 20 min. at room temperature to block en-
dogenous peroxidase activity. After blocking non-specific
protein bindings by an overnight incubation with Block
Ace (Dainippon, Inc., Osaka, Japan), the sections were in-
cubated with primary antibodies against human p53
(1:100), bcl-2 (1:100), Ki-67 (1:100), CEA (1:100), EMA
(1:100), nm23-H1 (1:100), VEGF (1:50), FGF-2 (1:50)
and Ki-67 (1:50), respectively, at 4™Ž overnight. Subse-
quently, sections were incubated with the secondary an-
tiserum (1:500) for one hour, followed by an incubation
with peroxidase anti peroxidase (PAP) complex for 30
min. at room temperature. The sections were visualized
using a diaminobenzidine (DAB)/Metal Concentration
(10× ) and Stable Peroxide Substrate Buffer (1× ) system
(Pierce, Rockford, Illinois, U.S.A.). The sections were then
washed with water and counterstained with hematoxylin.
Immunohistological results were assessed semiquantita-
tively by two authors. The staining for p53, bcl-2, EMA,
CEA, nm23-H1, VEGF and FGF-2 proteins with the respec-
tive antibodies was considered positive if more than 10%
of tumor cells were immunoreactive. The Ki-67 labeling
index was determined by light microscopy with an oil-im-
mersion objective (magnification × 1,000) randomly
counting 1,000 tumor epithelial cells and expressing the
results as a percentage of positive cells. Microvessel densi-
ty was determined by counting in the area of the most in-
tense vascularization (hot spot) of each tumor, and the
average count (per 200×  field) was recorded.
Results
Clinical Results
Preoperative biopsy using a 14-gauge Tru-cut biopsy nee-
dle was performed for 3 patients, however only one was
diagnosed as thymic carcinoma and others were failed to
obtain a decisive diagnosis. Preoperative diagnoses of oth-
er remaining 5 patients were invasive thymomas by radi-
ological examinations. Therefore, only one patient
underwent preoperative chemotherapy that consisted of
intra-arterial infusion of cisplatin 100 mg and subsequent
systemic administration of cisplatin 25 mg and etoposide
100 mg. In this case, a partial response was obtained. Sur-
gical procedure was performed through median sternoto-
my. Curative resection could be done in 4 patients (50%).
In other 4 of remaining patients, the resection was incom-
plete due to invasion into adjacent organs and/or dissem-BMC Surgery 2002, 2 http://www.biomedcentral.com/1471-2482/2/3
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inated lesions. Postoperative radiotherapy was given with
a total dose of 40–60 Gy for 6 patients. One patient who
underwent incomplete resection and radiotherapy, was
also received chemotherapy that consisted of cisplatin 60
mg/m2 and etoposide 120 mg/m2. The median survival
times for all patients was 43.8 month and the overall cu-
mulative survival was 46.7% at 3 years. Operative mortal-
ity, defined as death within 30 days of surgery, did not
occur. However, one patient, who underwent incomplete
resection, died on postoperative day 39 of rapid tumor
growth and respiratory failure.
Although our series included small size of patient popula-
tion, we investigated a relationship between some clinical
factors and survival. The median survival times for pa-
tients with completely and incompletely resected disease
were 73.0 and 17.6 months, respectively. As shown in Fig.
1, there was a difference in survival between completely
and incompletely resected patients. Clinical stage, squa-
mous cell carcinoma and postoperative irradiation did
not show favorable results in our series (data not shown).
Prognostic value of histologic grading could not be inves-
tigated because there was only one patient with low-grade
tumor in our series.
Immunohistochemical results
Positive immunohistochemical stainings with p53 and
Ki-67 were confined to the nucleus of the tumor cells (Fig.
2). Lymphocytes and stromal cells were consistently un-
stained. Immunoreactivity of bcl-2, CEA, EMA, nm23-H1,
VEGF and FGF-2 were predominantly observed in the cy-
toplasm of the tumor cells (Fig. 2). Positive immunostain-
ing of p53, bcl-2, CEA, EMA, nm23-H1, VEGF and FGF-2
was detected in 5/8 (62.5%), 3/8 (37.5%), 4/8 (50%), 5/
8 (62.5%), 6/8 (75%), 5/8 (62.5%) and 3/8 (37.5%), re-
spectively. The Ki-67 labeling index (mean ± S.D.) was
7.01 ± 6.37 and microvessel density (mean ± S.D.) was
34.36 ± 16.7 (per 200×  field). Table 2 summarizes these
immunohistochemical results.
We previously investigated the expression of these pro-
teins in thymomas [14,15]. These studies demonstrated
that positive immunostaining of p53, bcl-2, CEA, EMA,
nm23-H1, VEGF and FGF-2 was found in 13/38 (34.2%),
6/38 (15.8%), 6/38 (15.8%), 10/38 (26.3%), 22/38
(57.9%), 12/38 (31.6%) and 5/38 (13.2%), respectively
[14,15]. They also showed that Ki-67 labeling index and
microvessel density of thymomas were 2.57 ± 4.52 and
8.7 ± 6.99, respectively [14,15]. When compared these re-
sults, the expression rates of these proteins in thymic car-
cinoma were higher than those in thymomas, indicating
the aggressiveness of thymic carcinoma.
Discussion
In the present study, the size of patient population is
small and follow-up period is variable and relatively
short. In spite of these limitations, our data showed that a
complete resection suggests a favorable result. Previous
Table 1: Clinical characteristics
Case Age Sex Histology Grading Stage Resection Preoperative 
therapy
Postoperative therapy
1 54 F Clear cell carcinoma high III complete none radiotherapy
2 64 F SCC low III complete none radiotherapy
3 19 F SCC high II complete chemotherapy none
4 65 F Small cell carcinoma high III complete none radiotherapy
5 67 M Adenosquamous cell carcinoma high III incomplete none none
6 47 F SCC high IVa incomplete none radiotherapy
7 55 F SCC high III incomplete none radiotherapy
8 59 M SCC high IVa incomplete none chemotherapy radiotherapy
SCC: squamous cell carcinoma.
Figure 1
Survival of patients having complete resection compared with
incomplete resection.
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studies also showed similar results [6,8]. On the other
hand, Hsu et al[5] showed a lack of efficacy of complete
resection, even though they showed longer median surviv-
al. We believe that surgical resection of the tumor is the
best treatment for thymic carcinoma.
Our small series could not show a favorable result of clin-
ical stage, squamous cell carcinoma and postoperative ra-
diotherapy, while previous studies demonstrated a
favorable result. Liu et al [8] found that clinical stage had
statistically significant influence on patients' survival.
Figure 2
Positive staining of p53 (A), bcl-2 (B), Ki-67 (C), CEA (D), EMA (E), nm23-H1 (F), VEGF (G), FGF-2 (H) and factor VIII (I) in
thymic carcinoma. Magnification 100× .
Table 2: Immunohistochemical results
Case p53 bcl-2 Ki-67 CEA EMA nm23 VEGF FGF-2 MVD
1-+ 2 . 9 --- - - 1 5 . 1
2 + - 10.2 - + + + - 17.2
3- - 0 . 6 --- - - 1 9 . 1
4 - - 14.6 + + + - - 44.3
5 + - 10.6 + + + + + 34.6
6 + - 15.3 - + + + - 36.2
7++ 0 . 9 + +++ + 4 5 . 1
8++ 1 . 1 +-++ + 6 3 . 3
MVD: microvessel density (per 200×  field)BMC Surgery 2002, 2 http://www.biomedcentral.com/1471-2482/2/3
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Some previous studies demonstrated that squamous cell
carcinoma was associated with a better outcome than oth-
er histological types [6,7,17]. Masaoka et al[17] reported
that 5-year survival was 65.6% in squamous cell carcino-
ma and 14.3% in other type. Although we could not in-
vestigate a prognostic value of histologic grading, Liu et
al[8] also reported that histologic grading had significant
influence on patients' survival. With regard to the role of
irradiation in the treatment of thymic carcinoma, Shimo-
sato et al [18] reported an apparent cure from radiothera-
py for an unresected squamous cell thymic carcinoma
with lung invasion. There had been demonstrated a trend
towards squamous cell carcinomas being radiosensitive
[18,19]. Our results were not consistent with these previ-
ous studies. However the number of patients in our series
was too small to permit meaningful correlation between
survival and clinical stage, histologic subtype and radio-
therapy. We believe that this discrepancy might be due to
limited number of patients and combined treatment.
Our immunohistochemical results revealed that expres-
sion rates of p53, bcl-2, CEA, EMA and Ki-67 in thymic
carcinomas were higher than those in thymomas. Since
these proteins are related to tumor growth in many can-
cers, it is suggested that higher expression rates of these
proteins might indicate the aggressiveness of thymic carci-
noma.
Some previous studies also reported expression of these
proteins in thymic carcinomas. With regard to p53 expres-
sion in thymic carcinoma, previous studies had also re-
ported similar findings. Tateyama et al [9] reported 13 of
13 (100%), Hayashi et al[10] showed 5 of 6 (83.3%),
Chen et al[11] reported 12 of 17 (71%) and Hino et al
[12] found 14 of 19 (74%) thymic carcinomas were posi-
tive for p53 immunostaining. Tateyama et al[9] also re-
ported that p53 gene mutation occurred early in the
tumorgenesis of thymic tumors and p53 may be a useful
adjunct to differentiate thymic carcinoma from thymoma.
Bcl-2 is a proto-oncogene inhibiting apoptosis and Chen
et al[11] showed that bcl-2 expression correlates with ag-
gressiveness in thymic epithelial neoplasms. With regard
to CEA expression, Savino et al[20] reported that CEA
might act as a growth factor for proliferating thymic epi-
thelial cells. Some previous studies also reported expres-
sion of EMA in thymic carcinoma. Truong et al [3] showed
13 of 13 and Fukai et al[13] showed 13 of 14 thymic car-
cinomas were positive for EMA. Fukai et al[13] concluded
that immunolabeling for EMA appears to be a useful tool
for determining the degree of malignant disease among
thymic epithelial neoplasms. Therefore, taken together
with our results, expression of p53, bcl-2, CEA, EMA and
Ki-67 might be implicated in malignant potential of
thymic carcinoma.
In the present result, 75% of our series showed positive for
nm23-H1 expression. To our knowledge, there are no pre-
vious studies for nm23-H1 expression in thymic carcino-
ma. Expression of nm23-H1 is thought to play a specific
biological role in suppressing tumor metastasis [21]. The
role of high frequency of nm23-H1 expression in thymic
carcinoma deserves further investigation.
Angiogenesis is essential for tumor growth and an en-
hanced vascular supply might reflect a malignant poten-
tial [22]. Our result also showed that microvessel density
and expression of VEGF and FGF-2 in thymic carcinomas
were higher than those in thymomas. Therefore, angio-
genesis might be also related with the aggressiveness of
thymic carcinoma.
The outcome of thymic carcinoma treatment must be in-
vestigated using the same histologic typing and staging.
Thus, our series might be inadequate to analyze the bio-
logical characteristics of thymic carcinoma. In spite of lim-
ited number of patients and combined treatment, we
found that a complete resection suggests a favorable re-
sult. Furthermore, immunohistochemical results might
indicate the aggressiveness of thymic carcinoma. Further
study is warranted to define the biological characteristics
and precise treatment strategy for thymic carcinoma.
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